Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes

Table 1—

Study protocols of the patients in the trials considered in the meta-analysis

Sibutramine group
Placebo group
Study duration (months) Antidiabetic treatment
Drug dosage Patients (n) Patients (n)
Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy (ref. 10) 15 mg 69 65 6 Sulphonylurea
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin (ref. 11) 15 mg 68 64 12 Metformin
A randomized trial of sibutramine in the management of obese Type 2 diabetic patients treated with metformin (ref. 11) 20 mg 62 64 12 Metformin
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control (ref. 14) 20 mg 29 25 6 Metformin, sulphonylurea
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus (ref. 12) 5/20 mg 89 86 6 Metformin, sulphonylurea
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study (ref. 13) 15 mg 47 44 3 Insulin, metformin, sulphonylurea
Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial (ref. 15) 10 mg 44 42 12 Glibenclamide
Health-related quality of life in a randomized placebo-controlled trial of sibutramine in obese patients with type II diabetes (ref. 16) 15 mg 114 122 12 Hypocaloric diet
One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial (ref. 17) 10 mg 30 29 12 Hypocaloric diet
Total 552 541
  • In all the studies, diet was reduced in calories and specific dietary recommendations were given to the patients.

This Article

  1. Diabetes Care vol. 28 no. 4 942-949